Axon Heads Into Earnings at $607 With Bulls and Street Pointing Higher

AXON reports Q2 results after today's close with the stock riding a sharp pre-earnings rally — up 5.4% on Tuesday and 10.9% across the past week to $607.20 — and most of the data pointing in one direction.

Short interest is modest but worth noting as context: bears hold roughly 4.9% of the free float short, a position that has crept up about 5% over the past week but remains some 6% smaller than a month ago. The lending market is nowhere near stressed — availability runs at 524%, meaning there are more than five shares available to borrow for every one currently lent out, and the cost to borrow has eased to 0.45%, down sharply from levels closer to 0.56% seen through late July. Options positioning tells a similarly calm story. The put/call ratio is running at 1.00, fractionally below its 20-day average and half-a-standard-deviation on the bullish side of neutral — well off the defensive posture seen in late June when the ratio was above 1.10. Neither short sellers nor options traders are visibly bracing for a downside surprise.

The analyst community has been directionally constructive in the run-up. Piper Sandler lifted its target to $724 in mid-July, and Needham pushed to $750 on July 6 — both maintaining positive ratings ahead of the print. The consensus mean target sits around $662, which implies the stock's recent surge has narrowed but not closed the gap to fair value on most Street models. Bears point to Axon's heavy dependence on a single market segment and questions about whether newer bets in healthcare and drone technology can meaningfully move the revenue needle. Bulls counter that recurring software revenue continues to expand, international penetration is accelerating, and acquisitions like Dedrone open a credible counter-UAS growth lane. The valuation is not cheap — the trailing P/E runs near 56x and EV/EBITDA above 38x — but those multiples have compressed modestly over the past month as earnings have grown into the price.